Aims & Scope
Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pathobiology, and pharmacology of tumors of the kidney with the objective of improving diagnosis, treatment, and survivorship in patients. The journal is directed primarily at researchers and clinicians working on these areas, with some content aimed at patients/patient advocates with these conditions. With this objective in mind, the journal publishes original research reports, systematic and regular reviews, short communications, and letters-to-the-editor in basic science, translational research and clinical medicine. The journal is committed to the highest ethical standards and best practices, and prospective authors are encouraged to consult the relevant author instructions and policies on the website at the time of submission as these are updated regularly to reflect changing guidelines.
Why Publish with Kidney Cancer
Editorial Board
Editors-in-Chief
Primo N. Lara, Jr., MD
University of California Davis Comprehensive Cancer Center
Sacramento, CA
USA
Email: kca@iospress.com
(Epidemiology, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)
Peter Mulders, MD, PhD
Radboud UMC
Nijmegen
The Netherlands
Email: kca@iospress.com
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)
Associate Editors
Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City
USA
(Diagnosis, Treatment, Survivorship)
Laurence Albiges, MD, PhD
Gustave Roussy, Université Paris Saclay, Villejuif
France
(Epidemiology, Pharmacology, Diagnosis, Treatment, Survivorship)
Axel Bex, MD, PhD
Netherlands Cancer Institute, Amsterdam
The Netherlands
(Epidemiology, Diagnosis, Treatment)
Enrique Grande, MD
MD Anderson Cancer Center Madrid, Madrid
Spain
(Epidemiology, Diagnosis, Treatment, Survivorship)
Viktor Grünwald, MD
University Hospital Essen, Essen
Germany
(Etiology, Diagnosis, Treatment)
Shilpa Gupta, MD
Cleveland Clinic, Cleveland, OH, USA
(Epidemiology, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)
Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center, Houston
USA
(Etiology, Molecular Genetics, Pharmacology, Diagnosis, Treatment, Survivorship)
Bradley C. Leibovich, MD
Mayo Clinic, Rochester
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Diagnosis, Treatment)
Egbert Oosterwijk, PhD
Radboud UMC, Nijmegen
The Netherlands
(Diagnosis, Treatment, Survivorship)
Javier Puente, MD, PhD
Hospital Clinico Universitario San Carlos, Madrid
Spain
(Diagnosis, Treatment, Survivorship)
Manuela Schmidinger, MD
Medical University of Vienna, Vienna
Austria
(Epidemiology, Pharmacology, Diagnosis, Treatment, Survivorship)
Sandy Srinivas, MD
Stanford University, Stanford
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)
Social Media Editor
Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City
USA
(Diagnosis, Treatment, Survivorship)
Associate Editors for Reviews
Enrique Grande, MD
MD Anderson Cancer Center Madrid, Madrid
Spain
(Epidemiology, Diagnosis, Treatment, Survivorship)
Sumanta Pal, MD
City of Hope, Duarte
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)
Editor of Clinical Trials Corner
Mamta Parikh, MD
UC Davis Comprehensive Cancer Center, Sacramento
USA
(Diagnosis, Treatment, Survivorship)
Editorial Board
Hideyuki Akaza, MD
University of Tokyo, Tokyo
Japan
(Pathogenesis, Diagnosis, Treatment)
Stephanie A. Berg, DO
Dana-Farber Cancer Institute, Boston, MA, USA
(Survivorship, Diagnosis, Treatment)
Cristiane Decat Bergerot, PhD
Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa, Grupo Oncoclinicas, Brasilia
Brazil
(Survivorship, Supportive Care)
Georg A. Bjarnason, MD, FRCP(C)
Sunnybrook Odette Cancer Center, Toronto, ON
Canada
(Molecular Genetics, Pharmacology, Diagnosis, Treatment, Survivorship)
Maria T. Bourlon, MD, MS
Instituto Nacional de Ciencias Médicas y Nutrición Salvador
Zubirán, Mexico City, Mexico
(Immunotherapy, Biomarkers, Epidemiology, Diagnosis, Treatment, Survivorship)
James Brugarolas, MD, PhD
University of Texas Southwestern Medical Center, Dallas, TX
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)
Ronald M. Bukowski, MD
Cleveland Clinic Foundation, Cleveland
USA
(Diagnosis, Treatment, Survivorship)
Steven C. Campbell, MD, PhD
Cleveland Clinic, Cleveland, OH
USA
(Epidemiology, Diagnosis, Treatment, Survivorship)
Toni K. Choueiri, MD
Dana-Farber Cancer Institute, Boston
MA, USA
(Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)
Marc Dall’era, MD
UC Davis Comprehensive Cancer Center, Sacramento, CA
USA
(Epidemiology, Diagnosis, Treatment)
Tanya B. Dorff, MD
City of Hope, Duarte, CA
USA
(Diagnosis, Treatment)
Janice P. Dutcher, MD
Cancer Research Foundation, Chappaqua, NY
USA
(Epidemiology, Diagnosis, Treatment, Survivorship)
Minas P. Economides, MD
NYU Grossman School of Medicine, NY
USA
(Pathogenesis, Pharmacology, Diagnosis, Treatment)
Tim Eisen, PhD, FRCP
University of Cambridge and Roche (VP and Global Head of GU Oncology Product Development), Cambridge
United Kingdom
(Pathobiology, Pharmacology, Diagnosis, Treatment)
Roy Elias, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, MD, USA
(Etiology, Molecular Genetics, Pathogenesis, Treatment)
Robert A. Figlin, MD, FACP
Cedars-Sinai Medical Center, Los Angeles, CA
USA
(Pathobiology, Diagnosis, Treatment, Survivorship)
Thomas (Tom) Flaig, MD
University of Colorado School of Medicine, Aurora, CO
USA
(Diagnosis, Treatment)
Jorge Garcia, MD, FACP
University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center, Cleveland, OH
USA
(Diagnosis, Treatment)
Dan George, MD
Duke University School of Medicine, Durham, NC
USA
(Epidemiology, Pathobiology, Pharmacology, Diagnosis, Treatment)
Ugo De Giorgi, MD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Italy
(Diagnosis, Treatment)
Shuchi Gulati, MD, MS
UC Davis Comprehensive Cancer Center, Sacramento, CA
USA
(Etiology, Molecular Genetics, Pharmacology, Diagnosis and Treatment)
Rudolfo De Guzman, MD
National Kidney and Transplant Institute, Metro Manila
Philippines
(Diagnosis, Treatment)
John Haanen, MD, PhD
Netherlands Cancer Institute, Amsterdam
The Netherlands
(Diagnosis, Treatment)
Naomi Haas, MD
University of Pennsylvania, Philadelphia, PA
USA
(Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)
Hans Hammers, MD, PhD
University of Texas Southwestern, Dallas, TX
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)
Michael R. Harrison, MD
Duke Cancer Institute, Durham, NC, USA
(Diagnosis, Treatment)
Daniel Heng, MD, MPH
Tom Baker Cancer Center, Calgary, AB
Canada
(Epidemiology, Diagnosis, Treatment, Survivorship)
Michelle S. Hirsch, MD, PhD
Brigham and Women's Hospital, Harvard Medical School, Boston, MA
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology)
James J. Hsieh, MD, PhD
Washington University School of Medicine, St. Louis, MO
USA
(Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)
Thomas Hutson, DO, PharmD
US Oncology/Baylor, Houston, TX
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)
Christian Kollmannsberger, MD
BC Cancer Agency, Vancouver, BC
Canada
(Diagnosis, Treatment)
James Larkin, MD, PhD
The Institute of Cancer Research, London
United Kingdom
(Diagnosis, Treatment)
Marston Linehan, MD
National Cancer Institute, Bethesda, MD
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)
Borje Ljungberg, MD, PhD
Umea University, Umea, Sweden
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)
Jose Mauricio Mota, MD, PhD
São Paulo State Cancer Institute, University of São Paulo, São Paulo
Brazil
(Etiology, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)
Moshe C. Ornstein, MD
Cleveland Clinic, Cleveland, OH
USA
(Diagnosis, Treatment)
Susanne Osanto, MD, PhD
Leiden University Medical Center, Leiden
The Netherlands
(Diagnosis, Treatment, Survivorship)
Karima Oualla, MD, MSc
Sidi Mohamed Ben Abdellah University, Fes
Morocco
(Epidemiology, Diagnosis, Treatment, Survivorship)
Stephane Oudard, MD, PhD
Hôpital Européen Georges Pompidou, Paris
France
(Diagnosis, Treatment)
Allan J. Pantuck, MD
UCLA Institute of Urologic Oncology, Los Angeles
USA
(Molecular Genetics, Pathogenesis, Pharmacology, Diagnosis, Treatment)
Camillo Porta, MD
IRCCS San Matteo University Hospital Foundation, Pavia
Italy
(Diagnosis, Treatment)
Thomas Powles, MD
The Royal Free NHS Trust and Barts Cancer Institute, London
United Kingdom
(Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)
Brian Rini, MD
Cleveland Clinic, Cleveland, OH
USA
(Epidemiology, Etiology, Pathogenesis, Pathobiology, Diagnosis, Treatment, Survivorship)
Paul Russo, MD
Memorial Sloan Kettering Cancer Center, New York, NY
USA
(Diagnosis, Treatment)
Christopher Ryan, MD
Oregon Health Science University, Portland, OR
USA
(Diagnosis, Treatment)
Brian Shuch, MD
UCLA School of Medicine, Los Angeles, CA
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)
Andrey Soares, MD
Hospital Israelita Albert Einstein, São Paulo
Brazil
(Epidemiology, Diagnosis, Treatment)
Ramaprasad Srinivasan, MD, PhD
National Cancer Institute, Bethesda, MD
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Diagnosis, Treatment)
Walter Stadler, MD
University of Chicago, Chicago, IL
USA
(Epidemiology, Pharmacology, Diagnosis, Treatment)
Mark Stein, MD
Columbia University, New York, NY
USA
(Diagnosis, Treatment)
Cora N. Sternberg, MD
San Camillo and Forlanini Hospitals, Rome
Italy
(Diagnosis, Treatment)
Nizar M. Tannir, MD
MD Anderson Cancer Center, Houston, TX
USA
(Epidemiology, Pharmacology, Diagnosis, Treatment)
Yoshihiko Tomita, MD, PhD
Niigata University, Niigata
Japan
(Diagnosis, Treatment)
Ilya Tsimafeyeu, MD
Bureau for Cancer Research (BUCARE), New York, NY
USA
(Diagnosis, Treatment)
Robert G. Uzzo, MD
Fox Chase Cancer Center, Philadelphia, PA
USA
(Epidemiology, Etiology, Diagnosis, Treatment)
Ulka Vaishampayan, MD
University of Michigan, Rogel Cancer Center, Ann Arbor, MI
USA
(Epidemiology, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)
Guillermo de Velasco, MD, PhD
Hospital Universitario 12 de Octubre, Madrid
Spain
(Diagnosis, Treatment)
Martin H. Voss, MD
Memorial Sloan Kettering Cancer Center, New York, NY
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)
Stenio Zequi, MD, PhD
AC Camargo Cancer Center, Sao Paulo
Brazil
(Epidemiology, Diagnosis, Treatment)
Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center, Dallas, TX
USA
(Pharmacology, Diagnosis, Treatment)
Patricia Zondervan, MD, PhD
Amsterdam UMC, Amsterdam
The Netherlands
(Etiology, Molecular Genetics, Diagnosis, Treatment)
Author Guidelines
By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.
See instructions to authors.
Why Publish with Kidney Cancer
COPYRIGHT
Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.
Article sharing
IOS Press adopted Sage’s Article Sharing Policy from 8th of July 2024.
Please go to: Sage’s Author Archiving and Re-Use Guidelines | SAGE Publications Ltd for details. If your manuscript was submitted prior to 8th of July 2024, please contact editorial@iospress.nl with details of your enquiry.
Please visit the IOS Press Authors page for further information.
Abstracted/Indexed in
Cabell's Guide or Directory
DOAJ - Directory of Open Access Journals
Embase
Google Scholar
Scopus
Web of Science: Emerging Sources Citation Index
Open Access/Article Charges
Open Access Pricing
Kidney Cancer is an open access journal. This means that every article, from the time it is first posted as a pre-press article to when it is included as part of an online volume, is immediately, permanently, and openly available for readers to view, download, share, and reuse.
The APC for this journal is US$2800.
Authors may be eligible for discounts to their APC via open access agreements that Sage has with participating institutions. Discounts depend on the terms of the agreement, find out if your institution is participating by visiting the institutional agreements page at IOS Press. Eligibility is determined by the corresponding author’s affiliation at acceptance matching an agreement.
Your article may be eligible for a full or partial waiver due to our participation in initiatives to increase accessibility to publication across the international academic community. More information about discounts and eligibility.
PubMedCentral deposits
This journal deposits open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library but can only do so if the article received NIH funding, or if any of the authors are affiliated with NIH, or associated with US Federal agency or private or international partners. Please refer the NIH Public Access Policy for the full list of participating funders and other details.
Peer Review Policy
Kidney Cancer operates a rigorous, timely, blinded peer review process (single blind by default, with an option for double-blind if requested) by experts in the field. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.
After automatic plagiarism screening through iThenticate, all submitted manuscripts are subjected to initial appraisal by the Editors-in-Chief.
Manuscripts that are deemed unsuitable may be rejected without external review by the Editors-in-Chief and/or the Associate Editors and the authors will be informed as soon as possible.
Reasons to reject a paper in the pre-screening process could for example be because the work does not fall within the aims and scope of the Journal, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.
If found suitable for further consideration, manuscripts are forwarded to an Associate Editor(AE) with expertise in the area who performs a second review and if determined to be of sufficient interest, then recruits appropriate referees. The AE will invite a sufficient number of reviewers to obtain at least 2 reviews.
Reviewers are asked to recuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include, but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s). The Editors-in-Chief strive to ensure a typical turnaround time of 3 months from submission to final determination of status.
Reviewers are asked to judge a paper on at least:
- Significance to field
- Relevance to journal
- Methodology
- Data analysis
- Literature review
- Writing style/clarity
Based on the received reviews the Associate Editor will write a decision letter, choosing one of the following categories:
- Accept
The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
- Minor revisions required
The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Associate Editor and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- Major revisions required
The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- Revise and resubmit
In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.
- Reject
The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
The Editors-in Chief may perform a secondary review and suggest additional revisions. After final inspection and approval of the decision letter by the Editors-in-Chief the authors are notified of the decision.
Once accepted, manuscripts are normally published on-line without delay (with the date of publication indicated) and appear in the next available print issue (published quarterly).
Co-authors who are also members of the Editorial Board are not involved in any way with the peer review process of articles of their (co-)authorship, and are asked to disclose this information in the Conflict of Interest section.
The Editors-in-Chief have ultimate responsibility for what is published in the journal.
Authors may appeal decisions by contacting the Editors-in-Chief (at kca@iospress.com).
The Editors-in-Chief aim to inform authors in writing of the result of their appeal within 14 days.
Archives of original submissions, referee reports, revisions and correspondence for both accepted and rejected manuscripts are kept indefinitely.
Social Media – Follow the journal on Twitter and keep updated as the social media editor Neeraj Agarwal, MD shares our journal content and news of interest to the kidney cancer research community. Join in the discussion with our research community!
Emerging Sources Citation Index – As of July 2021, Kidney Cancer is covered in the Emerging Sources Citation Index in the Web of Science.
Kid. Can. Assoc. Partnership – As of Nov 2017, a new partnership was announced between the Kidney Cancer Association (kidneycancer.org) and our journal Kidney Cancer, which is a forum for important scientific advancements and the advocacy community.
Sustainable Development Goals
The content of this journal relates to SDG:
Visit the SDG page for more information.
Supporting Diversity and Inclusion
This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.
More information will be available in due course. Check the SDGs page for updates.
 |
